**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | EP Lung Prague | **Project Code** | PB4LEP100 |
| **Virtual Project Manager** | Saskia Speth | **Clinical Program Manager** | Sanneke Koekkoek |
| **Compliance** | Choose an item. | **Editor** | Trudy Stoddert |

**Launch Date/Internal Launch Date:**

**Project Type**

Webcast

Downloadable Slides

CD/DVD

Podcast

Other:

**Email Blast Included?**

Yes

No

Subject Line:

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests: Incl meeting participants

**Cross Promotion**

Yes

No

If Yes, List Activities:

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By:

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):  
  
Content Available by:

**CME?**

Yes

No

**CME Posttest Link:**

**Webcast/PDS URL:** www.prIMEoncology.com/eplung\_Prague2014\_PDS

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title:**

**LIVE MEETING-ASSOCIATED VIRTUAL ACTIVITIES**

1. **[Meeting-Associated Downloadable Slides]---VERIFY with Clinical after the meeting to see what presentation are to be included**

**Downloadable Slides From Expert PracticeSM in Lung Cancer**

**ACTIVITY FEATURES**

[Icon] Downloadable Slides [Insert screen shot]

**ACTIVITY OVERVIEW**

prIME Oncology invites you to view Downloadable Slides from the Expert PracticeSM in Lung Cancer meeting held in Prague, Czech Republic.

**PROVIDER**

This activity is provided by prIME Oncology.

**[Tab—Lung Cancer]**

Discussant: **Keith Kerr, MBChB, FRCPath,** Aberdeen Royal Infirmary, Aberdeen, United Kingdom

Topic: The role of pathology in the era of targeted therapy

Learning Objective: Evaluate lung cancer biomarkers to inform choice of treatment strategy for non-small cell lung cancer (NSCLC), including optimal methods for tissue sampling, analysis, and evaluation of results

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Solange Peters, MD, PhD,** Multidisciplinary Oncology Center Lausanne, Lausanne, Switzerland

Topic: Keynote lecture—Immunotherapy: A step forward in treatment of advanced NSCLC

Learning Objective: Identify the role of immunotherapy in lung cancer, in particular the role of checkpoint inhibition, and evaluate efficacy and safety of these treatments in NSCLC

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Wolfgang Jungraithmayr, MD, PhD,** University Hospital Zurich, Zurich, Switzerland

**Benjamin Besse, MD, PhD,** Institut Gustave Roussy, Villejuif, France

**Umberto Ricardi, MD, PhD,** University of Turin, School of Medicine, Turin, Italy

Topic: Case #1—Stage III NSCLC: What’s the best multimodality approach?

Learning Objective: Adopt a multidisciplinary approach for the care of patients with lung cancer

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Benjamin Besse, MD, PhD,** Gustave Roussy, Villejuif, France

Topic: Case #2—Advanced NSCLC: Treatment strategies in the absence of targetable driver mutations

Learning Objective: Evaluate and incorporate the latest clinical trial data describing the use of chemotherapy and targeted agents in the choice of first-line, second-line, and maintenance therapy in lung cancer

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Natasha Leighl, MD, MMSc, FRCPC,** Princess Margaret Hospital, Toronto, Ontario, Canada

Topic: Case #3—Adenocarcinoma with *ALK* rearrangement: Selecting optimal approach

Learning Objective: Evaluate and incorporate the latest clinical trial data describing the use of chemotherapy and targeted agents in the choice of first-line, second-line, and maintenance therapy in lung cancer

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Anne-Marie Dingemans, MD, PhD,** Maastricht University Medical Center,   
 Maastricht, the Netherlands

Topic: Case #4—*EGFR*-mutated advanced NSCLC: Evaluating treatment options

Learning Objective: Evaluate and incorporate the latest clinical trial data describing the use of chemotherapy and targeted agents in the choice of first-line, second-line, and maintenance therapy in lung cancer

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Natasha Leighl, MD, MMSc, FRCPC,** Princess Margaret Hospital, Toronto, Ontario, Canada

Topic: Case #5—Squamous cell lung carcinoma: The changing treatment paradigm

Learning Objective: Recognize the emerging treatment options for squamous cell NSCLC in order to provide best care for patients with these forms of lung cancer

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\*\*\*Just use the CME section below from the Webcast section for an ACCME-certified PDS\*\*\*

1. **[Meeting-Associated Webcast]---VERIFY with Clinical after the meeting to see what presentation are to be included**

**~~Insert Meeting Title~~**

**~~ACTIVITY FEATURES~~**

~~[Icon] Interactive Presentation~~

~~[Icon] Downloadable Slides~~

~~[Icon] Podcast (if appropriate)~~

~~[Icon] CME-Certified (if appropriate)~~

**~~ACTIVITY OVERVIEW~~**

~~This [CME-certified (if appropriate)] Webcast contains~~ **~~video and downloadable slides~~** ~~from the symposium/meeting [choose one] [Meeting Title], a prIME Oncology educational activity that was held on [insert date], in [insert location].~~

**~~TOPICS~~**

~~[Insert Agenda topic]~~

~~[~~*~~Insert presenter name and degree(s)]~~*

~~[Insert Agenda topic]~~

~~[~~*~~Insert presenter name and degree(s)]~~*

~~[Insert Agenda topic]~~

~~[~~*~~Insert presenter name and degree(s)]~~*

**~~FACULTY~~**

**~~Name, degree(s)~~**

~~Institution~~

~~City, State, Country~~

**~~Name, degree(s)~~**

~~Institution~~

~~City, State, Country~~

**~~Name, degree(s)~~**

~~Institution~~

~~City, State, Country~~

**TARGET AUDIENCE**

This educational activity is intended for medical oncologists, radiotherapists, thoracic surgeons, pulmonologists, pathologists, and other healthcare professionals interested and/or involved in the treatment of patients with non-small cell lung cancer (NSCLC).

**LEARNING OBJECTIVES**

After successful completion of this educational activity, participants should be able to:

* Evaluate lung cancer biomarkers to inform choice of treatment strategy for NSCLC, including optimal methods for tissue sampling, analysis, and evaluation of results
* Identify the role of immunotherapy in lung cancer, in particular the role of checkpoint inhibition, and evaluate efficacy and safety of these treatments in NSCLC
* Adopt a multidisciplinary approach for the care of patients with lung cancer
* Evaluate and incorporate the latest clinical trial data describing the use of chemotherapy and targeted agents in the choice of first-line, second-line, and maintenance therapy in lung cancer
* Recognize the emerging treatment options for squamous cell NSCLC in order to provide best care for patients with these forms of lung cancer

**~~CONTINUING MEDICAL EDUCATION [if applicable]~~**

~~prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.~~

~~prIME Oncology designates this live activity for a maximum of XX~~ *~~AMA PRA Category 1 Credits™.~~* ~~Physicians should claim only the credit commensurate with the extent of their participation in the activity.~~

**~~METHOD OF PARTICIPATION [if applicable]~~**

~~There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the~~ [~~Terms of Use.~~](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx)

~~Links to the posttest are available on the video player pages.~~

~~In order to receive credit, participants must successfully complete the online posttest with XX% or higher.~~

**PROVIDER**

This activity is provided by prIME Oncology.

**SUPPORTER**

This educational activity is supported by F. Hoffmann-La Roche Ltd. and Foundation Medicine.

**ACTIVITY DATE**

Release Date: 31 January 2015

Expiration Date: 31 January 2016

**MOBILE APP VIEW ACTIVITY TEXT PER VIDEO**EP Lung Prague

1. **Web Activity Page Titles**

Landing Page Title: Expert Practicesm in Lung Cancer  
Activity Page Title: [[Use Agenda Topics]]

1. **Meta Description  
   (One description for each page (including landing pages and all activity pages.** This should be roughly 150 characters in length. This is the short description that will appear beneath the activity title in search results, so it should be a compelling, keyword-rich description that will encourage the user to click)

This educational activity features expert in the field discussing challenging clinical scenarios in lung cancer, highlighting the most up-to-date state of art approach and emerging data of novel therapeutic strategies, including ongoing clinical trials.

1. **Key Words and Key Phrases  
   (Please included as many key words or phrases as are associated with the activity. 15 or more is ideal. These are words or phrases that a viewer might use in a web search. Please add one key word/phrase per line) Example:**

*NSCLC*

*Role of pathology of targeted therapy*

*Biomarker analysis*

*EGFR*

*ALK*

*KRAS*

*Driver mutations*

*HER2*

*BRAF*

*PIK3CA*

*AKT1*

*MAP2K1*

*MET*

*PDL1*

*Immunotherapy in advanced non-small lung cancer*

*Anti-CTLA4*

*Anti-PD1*

*Anti-PDL1multidisciplinary collaboration*

*Advanced NSCLC*

*Targetable driver mutations*

*EGFR-mutated advanced NSCLC*

*Adenocarcinoma*

*EML4-ALK*

*Squamous cell lung carcinoma*

1. **~~[Meeting-Associated Podcast]---VERIFY with Clinical after the meeting to see what presentation are to be included~~**

~~For each presentation:~~

~~Listing: City—Disease—Presenter~~

~~Description: [Name, degree(s)], from [Institution] discusses [insert topic description].~~